Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 2:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 428 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer of the Thyroid Clear all
Terminated No phase listed Observational

ctDNA in Patients With Thyroid Nodules

NCT02778412
View directory record Official record
Conditions
Thyroid Cancer, Thyroid Nodules, Thyroid Adenoma, Thyroiditis
Interventions
Not listed
Lead sponsor
Pathway Genomics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 13, 2026, 2:03 AM EDT
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 13, 2026, 2:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers

NCT00336102
View directory record Official record
Conditions
Breast Cancer, Fatigue, Hypothyroidism
Interventions
physiologic testing, fatigue assessment and management, management of therapy complications
Other · Procedure
Lead sponsor
University of South Florida
Other
Eligibility
20 Years to 80 Years · Female only
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
41
States / cities
Phoenix, Arizona • Greeley, Colorado • Loveland, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 13, 2026, 2:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

NCT00923247
View directory record Official record
Conditions
Medullary Thyroid Carcinoma
Interventions
Bortezomib, Vandetanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 13, 2026, 2:03 AM EDT
Active, not recruiting Phase 2 Interventional

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

NCT04544111
View directory record Official record
Conditions
Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Hurthle Cell Thyroid Neoplasia
Interventions
Trametinib, Dabrafenib, PDR001
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 13, 2026, 2:03 AM EDT
Not listed Not applicable Interventional

Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules

NCT01757834
View directory record Official record
Conditions
Thyroid Nodule
Interventions
SWUS Elastography
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

NCT01025453
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Temsirolimus and Sorafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 1 Interventional

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

NCT05241834
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Interventions
LOXO-260
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 13, 2026, 2:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

NCT07023731
View directory record Official record
Conditions
KRAS G12D Mutation, Advanced Solid Cancer
Interventions
ARV-806
Drug
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 13, 2026, 2:03 AM EDT
Recruiting No phase listed Observational

DESTINY-PANTUMOUR04

NCT07124000
View directory record Official record
Conditions
Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Trial of LBH589 in Metastatic Thyroid Cancer

NCT01013597
View directory record Official record
Conditions
Thyroid Carcinoma
Interventions
LBH589
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Green Bay, Wisconsin • Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 1 Interventional

Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma

NCT00673010
View directory record Official record
Conditions
Thyroid Cancer
Interventions
131 I-iodine (131-I), 124 I-iodine (124-I)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Not applicable Interventional

Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules

NCT00316823
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gene expression analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunohistochemistry staining method, needle biopsy
Genetic · Other · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Oct 13, 2026, 2:03 AM EDT
Recruiting No phase listed Observational

Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management

NCT04216732
View directory record Official record
Conditions
Advanced Thyroid Gland Medullary Carcinoma, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8
Interventions
Blood Pressure Measurement, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
San Francisco, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 13, 2026, 2:03 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers

NCT03892993
View directory record Official record
Conditions
Thyroid Gland Medullary Carcinoma
Interventions
Decision Aid, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 13, 2026, 2:03 AM EDT
Completed No phase listed Observational

Molecular Markers in Thyroid Cancer

NCT00598364
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Not listed
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
1 Year and older
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 1 Interventional

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

NCT00405405
View directory record Official record
Conditions
Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer, Melanoma, Stage IV Head and Neck Cancer
Interventions
Cisplatin, Docetaxel, Bevacizumab, Erlotinib, Radiotherapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Sutent Adjunctive Treatment of Differentiated Thyroid Cancer

NCT00668811
View directory record Official record
Conditions
Papillary Thyroid Cancer, Follicular Thyroid Cancer, Differentiated Thyroid Cancer
Interventions
SU011248, Sutent
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 13, 2026, 2:03 AM EDT
Recruiting Phase 1 Interventional

Brodalumab in the Treatment of Immune-Related Adverse Events

NCT06673329
View directory record Official record
Conditions
Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Thyroid Cancer, Gynecologic Cancer, Pancreatic Cancer, Stomach Cancer, Brain Tumor, Colon Cancer, Rectal Cancer, Head and Neck Cancer, Oral Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Interventions
Brodalumab, CT scan
Drug · Radiation
Lead sponsor
Brian Henick, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Not applicable Interventional

Accuracy of FDG-PET Scanning to Diagnose Malignant Thyroid Nodules

NCT00537797
View directory record Official record
Conditions
Thyroid Neoplasms
Interventions
FDG-PET Scan
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
3
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine

NCT00098813
View directory record Official record
Conditions
Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
Interventions
romidepsin, laboratory biomarker analysis, positron emission tomography
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Commack, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 13, 2026, 2:03 AM EDT
Completed Not applicable Interventional Results available

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

NCT00970359
View directory record Official record
Conditions
Thyroid Cancer
Interventions
AZD6244
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 13, 2026, 2:03 AM EDT
Recruiting No phase listed Observational

I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer

NCT06443866
View directory record Official record
Conditions
Thyroid Cancer, RAI-Refractory Thyroid Cancer
Interventions
Disease status detection, Theranostic dosimetry, I-124 PET/CT imaging
Diagnostic Test · Drug
Lead sponsor
Miami Cancer Research Center, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 13, 2026, 2:03 AM EDT
Terminated Phase 1Phase 2 Interventional

Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer

NCT00077103
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
filgrastim, pegfilgrastim, cisplatin, doxorubicin hydrochloride, fosbretabulin disodium, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
3
States / cities
Detroit, Michigan • Cleveland, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 13, 2026, 2:03 AM EDT